AssayIndex
Reports by quarter

Reports submitted in 2025-Q3 · page 4

Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. Median purity for the quarter is 99.03 % area, n=816. Read the 2025-Q3 state-of-the-index report →

816 records21 pagesmedian on this page 98.96 %updated 30 Jul 2026
ReportCompoundSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-019628NAD+TFCTFC-2505-C1792Janoshik2025-Q399.7211.1992.6Buyer-sourced0FAIL
AX-2025-019474BPC-157JEEPJEEP-2506-R8215Kestrel2025-Q399.243.6697.6Buyer-sourced0PASS
AX-2025-019260GHRP-6AMBAMB-2508-T5301Janoshik2025-Q399.764.91—Buyer-sourced0PASS
AX-2025-018965BPC-157ASYASY-{CAT}-1276VendorInvestigate2025-Q399.935.72103.0Buyer-sourced0PASS
AX-2025-020999TirzepatideWXTWXT-2505-T3334Janoshik2025-Q398.483.8893.0Buyer-sourced0PASS
AX-2025-020937SemaglutideWXTWXT-2508-G2836Janoshik2025-Q398.522.42—Laboratory-retained0PASS
AX-2025-020857CJC-1295 (no DAC)CPCCPC-2503-R1674Janoshik2025-Q397.365.5098.5Laboratory-retained0FAIL
AX-2025-0203665-Amino-1MQMKMMKM-2503-H3929Janoshik2025-Q399.015.45104.3Buyer-sourced0FAIL
AX-2025-019772RetatrutideHomopeptideHOMO-2508-U3892Janoshik2025-Q398.616.4498.4Buyer-sourced1MARGINAL
AX-2025-019697SelankTFCTFC-2504-G2332Janoshik2025-Q399.548.91—Buyer-sourced1MARGINAL
AX-2025-019305RetatrutideAMBAMB-2502-A6319Medutest2025-Q398.554.5196.8Buyer-sourced0PASS
AX-2025-019134NAD+GSPGSP-2507-A3926Janoshik2025-Q398.8411.68—Buyer-sourced0FAIL
AX-2025-018726SS-31 (Elamipretide)QSCQSC-2502-M6829VendorInvestigate2025-Q398.405.35104.5Buyer-sourced1FAIL
AX-2025-018503MOTS-cWWBWWB-2505-G2801Janoshik2025-Q399.423.25103.8Buyer-sourced1FAIL
AX-2025-018494MOTS-cWWBWWB-2505-G2801Janoshik2025-Q399.803.08—Buyer-sourced0PASS
AX-2025-020744SemaglutideSGNSGN-2502-F9009VendorInvestigate2025-Q399.415.5096.5Buyer-sourced2MARGINAL
AX-2025-020463GHRP-6KPKP-2503-L5154Janoshik2025-Q398.444.7099.7Buyer-sourced0FAIL
AX-2025-020376IpamorelinMKMMKM-2504-N4424VendorInvestigate2025-Q398.905.51100.7Laboratory-retained0FAIL
AX-2025-020149IpamorelinERPERP-2502-S9437Janoshik2025-Q398.783.6992.5Laboratory-retained0FAIL
AX-2025-019971SelankHJHJ-2507-F7054VendorInvestigate2025-Q399.158.26—Buyer-sourced0PASS
AX-2025-019727SemaglutideHomopeptideHOMO-2505-V3835PeptideMeter2025-Q398.445.98—Laboratory-retained0PASS
AX-2025-018947RetatrutideASYASY-{CAT}-1860Kestrel2025-Q399.065.9999.4Buyer-sourced0PASS
AX-2025-020844KPVCPCCPC-2502-M2176Medutest2025-Q398.603.40—Buyer-sourced0FAIL
AX-2025-020842KPVCPCCPC-2502-M2176Medutest2025-Q398.833.64—Supplier-supplied1FAIL
AX-2025-020417LiraglutideMKMMKM-2508-P4928Janoshik2025-Q398.167.2593.5Buyer-sourced0PASS
AX-2025-020098MK-677 (Ibutamoren mesylate)SWBSWB-2505-G8354Janoshik2025-Q399.682.7796.3Buyer-sourced0FAIL
AX-2025-019992SemaglutideSWBSWB-2504-Y6911VendorInvestigate2025-Q399.192.6793.1Buyer-sourced0PASS
AX-2025-019849SemaglutideHomopeptideHOMO-2506-M5731Janoshik2025-Q398.016.54—Buyer-sourced1MARGINAL
AX-2025-019528PEG-MGFTFCTFC-2507-M8937Kestrel2025-Q398.054.59—Buyer-sourced0PASS
AX-2025-019010VilonASYASY-{CAT}-1626Medutest2025-Q399.938.5789.9Supplier-supplied1FAIL
AX-2025-018864N-Acetyl Semax AmideFGPFGP-2508-R8995VendorInvestigate2025-Q398.449.52—Buyer-sourced0FAIL
AX-2025-018500MOTS-cWWBWWB-2505-G2801Janoshik2025-Q399.933.4793.9Buyer-sourced0PASS
AX-2025-021137TirzepatideSIGSIG-2505-6162Janoshik2025-Q398.384.6299.0Buyer-sourced0PASS
AX-2025-020457TirzepatideKPKP-2504-V5402Kestrel2025-Q398.804.5799.6Buyer-sourced1MARGINAL
AX-2025-020412LiraglutideMKMMKM-2508-P4928Janoshik2025-Q399.196.5493.9Supplier-supplied1MARGINAL
AX-2025-020347BPC-157MKMMKM-2502-T3877Janoshik2025-Q398.606.61—Buyer-sourced0PASS
AX-2025-020302MK-677 (Ibutamoren mesylate)GGPepsGGPE-2507-S2892Janoshik2025-Q399.794.9094.9Buyer-sourced0FAIL
AX-2025-019602TB-500TFCTFC-2503-R1539Janoshik2025-Q399.453.8597.7Buyer-sourced0PASS
AX-2025-019076GHRP-6GSPGSP-2508-F3139Janoshik2025-Q399.477.07—Buyer-sourced0PASS
AX-2025-019016VilonASYASY-{CAT}-1626Medutest2025-Q399.938.3799.2Buyer-sourced1FAIL